News
03-18-2010, 06:11 AM
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.
More... (http://www.news-medical.net/news/20100318/ZIOPHARM-Oncology-reports-net-income-of-2410M-for-quarter-ended-December-31-2009.aspx)
More... (http://www.news-medical.net/news/20100318/ZIOPHARM-Oncology-reports-net-income-of-2410M-for-quarter-ended-December-31-2009.aspx)